Neurodegenerative Disorders Research

Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005
ABN: 86 139 590 319
Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au
Web: www.ndr.org.au

Pride-HD

A Huntington's Disease Clinical Study

Aim

To evaluate the safety and tolerability of pridopidine at doses of 67.5 to 112.5 mg given twice daily to patients with Huntington's disease (HD), using the Unified Huntington's Disease Rating Scale, Total Motor Score (UHDRS-TMS) and Physical Performance Test (PPT) assessments

Hypothesis

Pridopidine, a dopaminergic stabiliser, improves cognition and motor function in patients with HD and that higher doses of pridopidine are more effective in improving motor impairment

The Study

A phase II, multicentre, multi-national, randomized, parallel-group, double-blind, placebo-controlled study, evaluating the safety and efficacy of pridopidine versus placebo

Status

Enrolment to commence Sept. 2014

Clinical Trial No NCT02006472

Funding

- Teva Pharmaceutical Industries Ltd
- Neurodegenerative Disorders Research Pty Ltd

Criteria

To be eligible for the Pride-HD Study participants must:

- have clinical features of HD (CAG repeats ≥36),
- be at least 21 years old with onset of HD after 18 years of age,
- have a weight of greater than 50 kg,
- be able to walk up stairs without assistance,
- be able to provide informed consent,
- have a reliable and willing caregiver,
- be willing to provide a blood sample for genetic analyses,
- be able to take oral medication, and
- not be pregnant, lactating or become pregnant.

Ethics approval

Bellberry Human Research Ethics Committee (02-078)

Contact

Professor Peter K Panegyres, MD PhD FRACP
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005
Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au